Weekly Digest – November 2024 Weekly Digest – November 2024 04 Nov 2024: CrossBridge Bio secures $10 million financing to advance the development of next-generation dual-payload ADC therapies CrossBridge Bio has raised $10 million in a seed financing round, led […]
Weekly Digest – November 2024 Weekly Digest – November 2024 04 Nov 2024: BigHat unveils next-gen ADC designed with Lonza’s Synaffix as lead program BigHat Biosciences has secured commercial licensing rights to Synaffix’s ADC technology to enhance its ADC pipeline […]
Weekly Digest – November 2024 Weekly Digest – November 2024 07 Nov 2024: AstraZeneca to build Antibody Drug Conjugate (ADC) manufacturing facility in Singapore AstraZeneca held a groundbreaking ceremony on November 7 for its new Antibody Drug Conjugate (ADC) Manufacturing […]
Weekly Digest – November 2024 Weekly Digest – November 2024 07 Nov 2024: ADC Therapeutics axes lead solid tumor drug after phase 1 setback, pivots to preclinical programs ADC Therapeutics has stopped the development of its lead solid tumor candidate, […]
Weekly Digest – November 2024 Weekly Digest – November 2024 06 Nov 2024: NextCure reports preclinical data for LNCB74 and additional clinical biomarker data for NC410 combo at Society for Immunotherapy of Cancer Annual Meeting NextCure announced preclinical data for […]
Weekly Digest – November 2024 Weekly Digest – November 2024 06 Nov 2024: Celltrion unveils development of two cancer drugs Celltrion unveiled two new ADC candidates, CT-P70 and CT-P71, at the World ADC 2024 conference, marking its first public disclosure […]
Weekly Digest – November 2024 Weekly Digest – November 2024 06 Nov 2024: MacroGenics pauses work on vobra duo ADC pending mature survival data MacroGenics has paused investment in vobra duo and related studies pending updated data from the Phase […]
